Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FSHR | P23945 | 12/20 | 0.66 |
| ▸ | TSHR | P16473 | 4/20 | 0.66 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | PTPRF | P10586 | 4/20 | 0.41 |
| ▸ | PTPN2 | P17706 | 4/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2195596 | 0.82 | FSHR (0.78) | FSHRTSHR | |
| SCHEMBL3655121 | 0.81 | FSHR (0.62) | FSHRTSHRNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2193422 | 0.80 | FSHR (1.00) | FSHRTSHR | |
| SCHEMBL2194582 | 0.79 | FSHR (0.61) | FSHRTSHRNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2193028 | 0.76 | FSHR (0.53) | FSHRTSHRNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2192026 | 0.75 | TSHR (0.68) | FSHRTSHR | |
| SCHEMBL2192816 | 0.75 | FSHR (0.56) | FSHRTSHRNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2191283 | 0.75 | FSHR (0.56) | FSHRTSHRNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2194212 | 0.73 | TSHR (0.61) | FSHRTSHRNPC1RAB9A | |
| SCHEMBL2196163 | 0.73 | TSHR (0.61) | FSHRTSHRNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9174940-B2 | TSH receptor antagonizing tetrahydroquinoline compounds | MERCK SHARP & DOHME B.V. (NL) | 2015-11-03 | — | — | US | claimed |
| US-20110172267-A1 | TSH receptor antagonizing tetrahydroquinoline compounds | N.V. ORGANON | 2011-07-14 | — | — | US | claimed |
| EP-2197445-A2 | TSH RECEPTOR ANTAGONIZING TETRAHYDROQUINOLINE COMPOUNDS | N.V. Organon (NL) | 2010-06-23 | — | — | EP | claimed |
| WO-2009027482-A2 | TSH RECEPTOR ANTAGONIZING TETRAHYDROQUINOLINE COMPOUNDS | N.V. ORGANON (NL) | 2009-03-05 | — | — | WO | claimed |
| EP-2197445-B1 | TSH RECEPTOR ANTAGONIZING TETRAHYDROQUINOLINE COMPOUNDS | MERCK SHARP & DOHME (NL) | 2017-04-19 | — | — | EP | disclosed |
| US-9174940-B2 | TSH receptor antagonizing tetrahydroquinoline compounds | MERCK SHARP & DOHME B.V. (NL) | 2015-11-03 | — | — | US | disclosed |
| US-20110172267-A1 | TSH receptor antagonizing tetrahydroquinoline compounds | N.V. ORGANON | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172267-A1 | TSH receptor antagonizing tetrahydroquinoline compounds | TSHR, MC1R, TRHR | FSHR 21/4885TSHR 1/4885NPC1 3891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.